Shares of Atrion Co. (NASDAQ:ATRI) have earned an average broker rating score of 5.00 (Strong Sell) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong sell recommendation.
Zacks has also assigned Atrion an industry rank of 124 out of 265 based on the ratings given to related companies.
Separately, BidaskClub cut shares of Atrion from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 9th.
Atrion (NASDAQ:ATRI) last announced its quarterly earnings results on Wednesday, November 8th. The medical instruments supplier reported $4.29 EPS for the quarter. The firm had revenue of $37.90 million during the quarter. Atrion had a net margin of 22.98% and a return on equity of 18.34%.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Neuberger Berman Group LLC lifted its stake in Atrion by 4.0% during the third quarter. Neuberger Berman Group LLC now owns 86,185 shares of the medical instruments supplier’s stock worth $57,916,000 after purchasing an additional 3,291 shares during the period. Vanguard Group Inc. lifted its stake in Atrion by 2.2% during the second quarter. Vanguard Group Inc. now owns 79,246 shares of the medical instruments supplier’s stock worth $50,979,000 after purchasing an additional 1,676 shares during the period. Dimensional Fund Advisors LP lifted its stake in Atrion by 1.6% during the third quarter. Dimensional Fund Advisors LP now owns 64,290 shares of the medical instruments supplier’s stock worth $43,203,000 after purchasing an additional 1,022 shares during the period. State Street Corp lifted its stake in Atrion by 3.0% during the second quarter. State Street Corp now owns 31,790 shares of the medical instruments supplier’s stock worth $20,446,000 after purchasing an additional 919 shares during the period. Finally, Janus Henderson Group PLC bought a new position in Atrion during the second quarter worth about $13,898,000. Hedge funds and other institutional investors own 59.09% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://sportsperspectives.com/2018/02/09/1608285.html.
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.